PPT - REVISION OF EUDRALEX VOL. 4 - GMP Luisa Stoppa, Ph.D. Inspection and Certification Department PowerPoint Presentation - ID:6720277
Update on the Clinical Trials Regulation (EU) No 536/2014 - Key developments
AIFA notice (update of the AIFA notice published on 12 March 2020) Clinical trials' management in Italy during the COVID-19 (
GUIDANCE ON THE MANAGEMENT OF CLINICAL TRIALS DURING THE COVID-19 (CORONAVIRUS) PANDEMIC Version 5 10/02/2022
Clinical Trials Regulation (CTR) for medicinal products in application on 31 January 2022
DIRECTIVE” 2001/20/EC
The Tao of Excellence on Twitter: "... good manufacturing practices (#GMPs) in the #clinicaltrial application, describes the content of the protocol synopsis,...3/5 #regulatoryaffairs #clinicalinvestigations #MDR #EU #Europe #clinicaltrials ...
Commission Guideline — Guidance on posting and publication of result-related information on clinical trials in relation to the
GUIDANCE DOCUMENTS CONTAINING THE COMMON PROVISIONS ON THE CONDUCT OF GCP INSPECTIONS BY COMPETENT AUTHORITIES OF THE DIFFERENT
Clinical Trials Toolkit Trial Supplies - PDF Free Download
Process Validation for IMPs: A Matter of Interpretation, or Mandatory?
Updated Draft Q&As for Clinical Trials Regulation 536/2014 released in EudraLex Volume 10
European Regulatory Framework and General Path to Market for ATMPs
Frontiers | Transitioning From Preclinical Evidence to Advanced Therapy Medicinal Product: A Spanish Experience
The Parallel Universes of Eudralex Vol 10 – JoBurmester.com
Guidance and Q&As - EMA
The CTR: what, when, why and how?
New Cro Audit Form | PDF | Clinical Trial | Audit
PDF) Clinical trial disclosure and transparency: Regulation EU No. 536/2014 Public disclosure at the clinical trial level
New documents in EudraLex Volume 10 Clinical trials guidelines including an updated CTA form
Frontiers | Advanced Therapy Medicinal Products' Translation in Europe: A Developers' Perspective
GMP for IMPs in View of the Revision of the EU Clinical Trial Provisions
Pharmaceuticals | Free Full-Text | Quality Assessment of Investigational Medicinal Products in COVID-19 Clinical Trials: One Year of Activity at the Clinical Trials Office | HTML
Clinical trials were missing from regulatory documents of extended-release methylphenidate for ADHD in adults: a case study of public documents - Journal of Clinical Epidemiology
REVISION OF EUDRALEX VOL. 4 - GMP - ppt download
PDF) Quality Assessment of Investigational Medicinal Products in COVID-19 Clinical Trials: One Year of Activity at the Clinical Trials Office
EudraLex - Volume 10 - Clinical trials guidelines UPDATED
